All In Biotech

Drug Trial Radar · NCT04501679

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 274 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

274

Actual

Start

Aug 11, 2020

Primary completion

Mar 30, 2022

Study completion Mar 31, 2022

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Aug 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.

Conditions

  • Prurigo Nodularis

Interventions

  • NemolizumabDrug

    Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.

  • PlaceboDrug

    Participants received matching placebo as SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16Time frame: Baseline, Week 16
  2. Number of Participants With an Investigator Global Assessment (IGA) Success at Week 16Time frame: Baseline, Week 16

Locations

74 sites in 9 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site

    Fountain Valley, California

  • Galderma Investigational Site

    San Diego, California

  • Galderma Investigational Site

    Washington D.C., District of Columbia

  • Galderma Investigational Site

    Aventura, Florida

  • Galderma Investigational Site

    Miami, Florida

  • Galderma Investigational Site

    North Miami Beach, Florida

  • Galderma Investigational Site

    Ormond Beach, Florida

  • Galderma Investigational Site

    Chicago, Illinois

  • Galderma Investigational Site

    Indianapolis, Indiana

  • Galderma Investigational Site

    Louisville, Kentucky

  • Galderma Investigational Site

    Boston, Massachusetts

  • Galderma Investigational Site

    Saint Joseph, Michigan

  • Galderma Investigational Site

    New York, New York

  • Galderma Investigational Site

    Cincinnati, Ohio

  • Galderma Investigational Site

    Dublin, Ohio

  • Galderma Investigational Site

    Anderson, South Carolina

  • Galderma Investigational Site

    Murfreesboro, Tennessee

  • Galderma Investigational Site

    Dallas, Texas

  • Galderma Investigational Site

    Dripping Springs, Texas

  • Galderma Investigational Site

    Pflugerville, Texas

  • Galderma Investigational Site

    Webster, Texas

  • Galderma Investigational Site

    Morgantown, West Virginia

  • Galderma Investigational Site

    Brussels, Belgium

  • Galderma Investigational Site

    Ghent, Belgium

  • Galderma Investigational Site

    Jette, Belgium

  • Galderma Investigational Site

    Leuven, Belgium

  • Galderma Investigational Site

    Liège, Belgium

  • Galderma Investigational Site

    Bathurst, Canada

  • Galderma Investigational Site

    Calgary, Canada

  • Galderma Investigational Site

    London, Canada

  • Galderma Investigational Site

    Markham, Canada

  • Galderma Investigational Site

    North York, Ontario, Canada

  • Galderma Investigational Site

    Bordeaux, France

  • Galderma Investigational Site

    Brest, France

  • Galderma Investigational Site

    Lille, France

  • Galderma Investigational Site

    Nantes, France

  • Galderma Investigational Site

    Nice, France

  • Galderma Investigational Site

    Paris, France

  • Galderma Investigational Site

    Paris, France

  • Galderma Investigational Site

    Pierre-Bénite, France

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.